Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Shares of pharma giant AstraZeneca (NYSE: AZN ) rose slightly today -- despite reporting mediocre third quarter earnings. Year-over-year revenue dropped, and sales took a hit after some of the company's high profile drugs lost patent protection this year.
In the following video, health care analysts Max Macaluso and David Williamson discuss these results, AstraZeneca's new CEO, and one of AstraZeneca's potential acquisition targets -- Amarin (Nasdaq: AMRN ) .
The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of its new triglyceride lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with our new premium research report. Click here now to keep reading.